{"product_id":"sprc-vrio-analysis","title":"SciSparc Ltd. (SPRC): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs SciSparc Ltd. (SPRC) truly positioned for sustainable success? Our rigorous VRIO analysis cuts straight to the core, examining whether its resources are Valuable, Rare, Inimitable, and Organized to capture a lasting competitive edge. Discover the definitive verdict on SciSparc Ltd. (SPRC)'s strategic strengths and weaknesses immediately below.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 1. Acquired MUSE™ Endoscopic System IP Portfolio (Nov 2025)\n\u003c\/h2\u003e\n\u003cp\u003eYou’re looking at a major strategic pivot for SciSparc Ltd., moving beyond its core pharmaceutical focus into the medical device space with this IP grab. The key takeaway here is that the value is high-potential, but the cost - in terms of dilution - is immediate and substantial.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue: Entering a Multi-Billion Dollar Niche\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThis acquisition immediately positions SciSparc to enter the global Gastroesophageal Reflux Disease (GERD) device market. That market was valued at about $2.5 billion in 2024 and is expected to grow to $3.03 billion by 2030. The MUSE™ system, designed for minimally invasive transoral fundoplication, targets a specific, high-value treatment area. Honestly, getting a full IP portfolio ready for commercialization is a huge shortcut past years of R\u0026amp;D.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTargets GERD device market projected to hit \u003cstrong\u003e$3.03 billion\u003c\/strong\u003e by 2030.\u003c\/li\u003e\n\u003cli\u003eLeverages Xylo’s prior success: a $3 million upfront payment from a 2019 licensing deal in Greater China.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity: A Large Asset for a Small Player\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eFor a company with a market capitalization around $2.82 million as of December 5, 2025, acquiring a complete, approved IP portfolio for a system like MUSE is quite rare. Most companies at this stage are either developing early-stage assets or acquiring smaller pieces of technology. This is a full package of patents and trademarks. It’s a big swing for a micro-cap firm.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability: Legal Moat, Execution Risk\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe patents and trademarks secured offer a strong legal barrier against direct copying, which is the definition of inimitability in this context. Still, the underlying technology’s commercial success isn't guaranteed by patents alone. Competitors can develop workarounds or superior next-generation devices, but they face a legal hurdle to copy this specific system. What this estimate hides is the time it takes to get regulatory approval in new territories like North America and Europe.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization: Commitment vs. Dilution\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSciSparc is definitely organizing to exploit this by committing a large chunk of equity. The deal requires issuing ordinary shares representing 19.99% of the company’s outstanding share capital upon closing. This shows serious commitment to integrating this asset class, but it’s a massive dilution event for existing shareholders. The plan is to replicate Xylo’s licensing model across North America, Europe, and Latin America.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on the payment structure:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset Acquired\u003c\/td\u003e\n\u003ctd\u003eConsideration Structure\u003c\/td\u003e\n\u003ctd\u003eDilution Impact\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMUSE™ IP Portfolio\u003c\/td\u003e\n\u003ctd\u003eOrdinary Shares or Pre-funded Warrants\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e19.99%\u003c\/strong\u003e of Issued \u0026amp; Outstanding Capital\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage Evaluation\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is potentially sustained, but only if the execution risk is managed. If they successfully license this IP into the targeted markets, the legal protection of the patents should translate into a long-term revenue stream. If they fail to secure strong distribution partners, the advantage evaporates quickly.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePotential Advantage: Sustained (if commercialization succeeds)\u003c\/li\u003e\n\u003cli\u003eCurrent Status: Temporary Advantage (due to high execution risk)\u003c\/li\u003e\n\u003cli\u003eKey Action: Finalize definitive agreements and secure regional distribution partners by Q2 2026.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinance: draft pro-forma capitalization table showing the impact of the \u003cstrong\u003e19.99%\u003c\/strong\u003e share issuance by Wednesday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 2. CNS\/Neuro-Therapeutic Drug Pipeline (via NeuroThera Labs Inc.)\n\u003c\/h2\u003e\n\u003cp\u003eSciSparc manages its CNS pipeline through its majority-owned subsidiary, NeuroThera Labs Inc., in which SciSparc holds approximately \u003cstrong\u003e75%\u003c\/strong\u003e, potentially rising to \u003cstrong\u003e84%\u003c\/strong\u003e upon fulfillment of pre-determined milestones.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eValue\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe pipeline holds drug candidates based on THC and\/or non-psychoactive CBD, with the transferred assets valued at approximately \u003cstrong\u003eUS$11.6 million\u003c\/strong\u003e in the transaction that established NeuroThera Labs.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDrug Candidate\u003c\/th\u003e\n\u003cth\u003eIndication(s)\u003c\/th\u003e\n\u003cth\u003eLatest Known Phase\/Status\u003c\/th\u003e\n\u003cth\u003eKey Result\/Metric\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-110\u003c\/td\u003e\n\u003ctd\u003eTourette Syndrome (TS)\u003c\/td\u003e\n\u003ctd\u003eFDA IND approved to proceed with Phase IIb trial\u003c\/td\u003e\n\u003ctd\u003ePhase IIb trial to be conducted at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-110\u003c\/td\u003e\n\u003ctd\u003eAlzheimer's Disease Agitation\u003c\/td\u003e\n\u003ctd\u003ePhase IIa (Investigator-Initiated) Positive Topline\u003c\/td\u003e\n\u003ctd\u003eDemonstrated a \u003cstrong\u003e23%\u003c\/strong\u003e reduction in agitation symptoms (CMAI); patients were free of delirium, oversedation, hypotension, or falls.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-210\u003c\/td\u003e\n\u003ctd\u003eASD and Status Epilepticus\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio transferred to NeuroThera\u003c\/td\u003e\n\u003ctd\u003ePart of the cannabinoid-based drug development programs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-160\u003c\/td\u003e\n\u003ctd\u003ePain\u003c\/td\u003e\n\u003ctd\u003ePart of the portfolio transferred to NeuroThera\u003c\/td\u003e\n\u003ctd\u003ePart of the cannabinoid-based drug development programs.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eThe enterprise value of NeuroThera Labs at the time of the asset transfer was approximately \u003cstrong\u003eUS$3.3 million\u003c\/strong\u003e, including approximately \u003cstrong\u003eUS$1.0 million\u003c\/strong\u003e in cash.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eRarity\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe specific combination of cannabinoid-based assets targeting TS, Alzheimer's agitation, ASD, status epilepticus, and pain within one controlled entity is unique to SciSparc's current structure.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eImitability\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eClinical trial data, such as the \u003cstrong\u003e23%\u003c\/strong\u003e reduction in agitation for SCI-110, and specific regulatory milestones, like the FDA IND approval for the Phase IIb TS trial, are difficult to replicate quickly.\u003c\/p\u003e\n\u003ch\u003e\u003ch\u003eOrganization\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe core pharma work is managed through the majority-owned subsidiary, NeuroThera Labs Inc. (TSXV: NTLX), which received the assets valued at \u003cstrong\u003eUS$11.6 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSciSparc committed \u003cstrong\u003eCAD 1,000,000\u003c\/strong\u003e (approximately \u003cstrong\u003eUS$716,000\u003c\/strong\u003e) to NeuroThera via an unsecured convertible note maturing October 22, 2027.\u003c\/li\u003e\n\u003cli\u003eSciSparc received \u003cstrong\u003e63,300,000\u003c\/strong\u003e common shares of Neurothera in the transaction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch\u003e\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\u003c\/h\u003e\n\u003cp\u003eThe advantage is temporary, contingent upon positive outcomes in the ongoing and planned clinical trials for SCI-110 and SCI-210.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 3. Scientific Advisory Board led by Professor Raphael Mechoulam\n\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eBoard expertise underpins R\u0026amp;D strategy, attracting investment and talent.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eData Point\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIsrael Prize Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eECNP Lifetime Achievement Award Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2006\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRothschild Prize Year\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2012\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eWorld-class, award-winning chair is exceptionally rare for a smaller-cap entity.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProfessor Mechoulam is globally acknowledged as the father of cannabinoid research.\u003c\/li\u003e\n\u003cli\u003eHe was among the first to complete the total synthesis of major plant cannabinoids, including THC, CBD, and CBG.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003ePersonal reputation and established networks are nearly impossible to replicate quickly.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\/Discovery\u003c\/td\u003e\n\u003ctd\u003ePatent Status\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCB2 Receptor Agonist (HU-433) for SCI-160\u003c\/td\u003e\n\u003ctd\u003eGranted in the U.S. and Europe\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEndocannabinoid System Discovery\u003c\/td\u003e\n\u003ctd\u003ePioneering scientific foundation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eGuidance is explicitly integrated into operations, evidenced by the product pipeline.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSCI-160 utilizes the HU-433 agonist synthesized by Professor Mechoulam.\u003c\/li\u003e\n\u003cli\u003eCannAmide™ (PEA formulation) contains 400mg active pharmaceutical ingredient per dose and holds a product license from Health Canada.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSustained advantage derived from scientific gravitas attracting high-caliber partners and assets.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug Candidate Platform\u003c\/td\u003e\n\u003ctd\u003eDevelopment Stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-110 (Tourette Syndrome, OSA, Alzheimer's)\u003c\/td\u003e\n\u003ctd\u003eClinical Trials Development Stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-210 (Autism Spectrum Disorder)\u003c\/td\u003e\n\u003ctd\u003eClinical Trial - First patient dosed March 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSCI-160 (Pain)\u003c\/td\u003e\n\u003ctd\u003ePre-clinical Stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eCompany Research \u0026amp; Development for the period ending December 31, 2024, was reported as -1.7m USD.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 4. Near-Zero Debt Capital Structure (FY 2025)\n\u003c\/h2\u003e\n\u003cp\u003eThe analysis below primarily utilizes the latest reported annual financial data available, specifically for Fiscal Year 2024 (ending December 31, 2024), to substantiate the near-zero debt structure premise.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe company maintained a low financial leverage position, evidenced by a reported \u003cstrong\u003eDebt \/ Equity Ratio\u003c\/strong\u003e of approximately \u003cstrong\u003e0.01\u003c\/strong\u003e for Fiscal Year 2024. This structure implies minimal fixed financing obligations, reducing vulnerability during operational or market downturns.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eFor a clinical-stage biotechnology entity, a Debt-to-Equity ratio near \u003cstrong\u003e0.01\u003c\/strong\u003e is uncommon, as this stage often necessitates debt financing to bridge development capital gaps. The reported \u003cstrong\u003eShort-Term Debt\u003c\/strong\u003e was \u003cstrong\u003e$0\u003c\/strong\u003e for FY 2024, FY 2023, FY 2022, FY 2021, and FY 2020.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe near-zero debt posture is primarily a result of strategic financing decisions, specifically favoring equity issuance over debt instruments. This is imitable by a competitor only through a conscious, sustained strategic choice to avoid leverage.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe organization has consistently prioritized equity financing, resulting in a clean balance sheet profile. Key financial figures from the latest reported full fiscal year (FY 2024) illustrate this structure:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTotal Shareholder Equity (FY 2024): \u003cstrong\u003e$8.94 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTotal Liabilities (FY 2024): \u003cstrong\u003e$1.40 million\u003c\/strong\u003e (Total Current Liabilities)\u003c\/li\u003e\n\u003cli\u003eTotal Assets (FY 2024): \u003cstrong\u003e$10.35 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe organization's structure is further detailed in the following comparative table:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric (Millions USD)\u003c\/th\u003e\n\u003cth\u003eFY 2024 (Dec '24)\u003c\/th\u003e\n\u003cth\u003eFY 2023 (Dec '23)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Assets\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e10.35\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11.18\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Liabilities\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.40\u003c\/strong\u003e (Current)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.57\u003c\/strong\u003e (Current)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Shareholder Equity\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e8.94\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e9.59\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShort-Term Debt\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDebt \/ Equity Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.01\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0.01\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe current advantage is \u003cstrong\u003eTemporary\u003c\/strong\u003e. While the lack of debt provides a significant financial buffer against immediate liquidity or solvency shocks, the company retains the strategic option to assume debt financing in the future, which would alter this competitive profile.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 5. Nasdaq Listing and Market Visibility (SPRC)\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Maintaining a listing on the Nasdaq Capital Market provides access to US capital markets and a level of institutional visibility that private or OTC-listed peers lack. The company's market capitalization, as recently reported, was approximately \u003cstrong\u003e$2.82 million\u003c\/strong\u003e as of December 5, 2025. The listing allows trading on an exchange where the Average Volume (20 Days) was reported as \u003cstrong\u003e3,361,028\u003c\/strong\u003e shares.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Listing on a major US exchange is not rare, but it is a necessary threshold for many institutional investors. The company's authorized share capital remains at \u003cstrong\u003e75,000,000\u003c\/strong\u003e Ordinary Shares.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e It requires meeting strict SEC and exchange requirements, which is a barrier to entry for smaller, non-compliant firms. The company previously faced non-compliance with Nasdaq Listing Rule 5550(a)(2), requiring a minimum bid price of \u003cstrong\u003e$1.00\u003c\/strong\u003e per share.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The recent 1-for-21 reverse share split in July 2025, reducing shares from \u003cstrong\u003e11,225,751\u003c\/strong\u003e to approximately \u003cstrong\u003e534,600\u003c\/strong\u003e, shows the organization is actively managing governance to maintain this listing.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary, as compliance costs and market conditions can threaten delisting if not managed carefully. The company's current ratio stands at \u003cstrong\u003e5.36\u003c\/strong\u003e, indicating strong liquidity.\u003c\/p\u003e\n\u003cp\u003eKey data points related to the Nasdaq listing structure and compliance efforts:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003ePre-Split Value (Approx.)\u003c\/td\u003e\n\u003ctd\u003ePost-Split Value (Approx.)\u003c\/td\u003e\n\u003ctd\u003eReference Date\/Event\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutstanding Ordinary Shares\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e11,225,751\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e534,600\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJuly 3, 2025 (Effective Date)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePublicly Held Shares\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e516,727\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePost-Split\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMinimum Bid Price for Compliance\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.00\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eNasdaq Listing Rule 5550(a)(2)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAuthorized Share Capital\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e75,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUnchanged\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eOrganizational actions taken to maintain listing visibility:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eReceived a 180-day extension from Nasdaq on January 14, 2025, with a deadline of July 14, 2025, to regain compliance with the minimum bid price rule.\u003c\/li\u003e\n\u003cli\u003eThe reverse share split was approved by shareholders on October 23, 2024.\u003c\/li\u003e\n\u003cli\u003eRegained compliance with Nasdaq Listing Rule 5550(a)(2) on July 18, 2025, after the closing bid price was at or above \u003cstrong\u003e$1.00\u003c\/strong\u003e per share for \u003cstrong\u003e10 consecutive business days\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 6. Recent Strategic Divestiture (MitoCareX Sale, Oct 2025)\n\u003c\/h2\u003e\n\u003cp\u003eThe divestiture of the majority-owned subsidiary MitoCareX Bio Ltd. to N2OFF, Inc. closed on October 23, 2025. SciSparc initially held a 52.73% ownership stake in MitoCareX.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe transaction provided an immediate cash infusion and a shift in strategic focus toward the CNS pipeline and the GERD IP.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTransaction Component\u003c\/th\u003e\n\u003cth\u003eSciSparc Financial\/Statistical Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash Consideration Received\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$700,000\u003c\/strong\u003e for 6,622 MitoCareX shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eN2OFF Equity Received (Sellers' Collective Share)\u003c\/td\u003e\n\u003ctd\u003e40% of N2OFF's fully diluted capital stock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Proceeds Entitlement (Sellers' Collective)\u003c\/td\u003e\n\u003ctd\u003e30% of N2OFF's financing proceeds over five years, \u003cstrong\u003ecapped at $1.6 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotential Milestone Upside\u003c\/td\u003e\n\u003ctd\u003eUp to 25% of N2OFF common stock\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eN2OFF Post-Closing Investment in MitoCareX\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$1 million\u003c\/strong\u003e cash investment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Reaction (SPRC Stock on Oct 23, 2025)\u003c\/td\u003e\n\u003ctd\u003eGain of 20.47%; Closing Price: $4.59; Valuation Impact: Approx. \u003cstrong\u003e$1M\u003c\/strong\u003e increase; Market Cap: \u003cstrong\u003e$7M\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe successful execution of a strategic divestiture to streamline operations is a singular event, not a recurring resource.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe intended selling valuation represented a 47% increase from SciSparc's initial investment valuation of $3.4 million in MitoCareX.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe strategic choice to divest is generally imitable; however, the specific realized financial terms and timing relative to the October 2025 closing date are unique to SciSparc's circumstances.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe completion of the transaction demonstrates organizational capability in executing complex M\u0026amp;A structures involving cash, equity exchange, and contingent consideration.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe transaction involved SciSparc, Dr. Alon Silberman, and Prof. Ciro Leonardo Pierri as 'Sellers'.\u003c\/li\u003e\n\u003cli\u003eThe deal involved the transfer of MitoCareX's proprietary algorithm, MITOLINE™, and in vitro screening systems.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe advantage is Temporary; the immediate financial benefit is realized upon closing, requiring subsequent execution on the remaining core assets to sustain value creation.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 7. Quantum-Powered 3D Protein Modeling Initiative\n\u003c\/h2\u003e\n\u003cp\u003eThe board of directors resolved to initiate the launch of the Initiative on September \u003cstrong\u003e16, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The initiative targets the use of quantum computing concepts for 3D protein modeling to revolutionize AI drug discovery, potentially accelerating R\u0026amp;D timelines significantly.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e Integrating quantum-adjacent technology into early-stage drug discovery modeling is cutting-edge and rare outside of major tech\/pharma collaborations.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e The specific algorithms and partnerships underpinning this initiative would be difficult to copy without deep technical know-how.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The company announced its resolve to launch this, indicating a strategic allocation of R\u0026amp;D budget toward this future-facing technology. The announcement led to a premarket stock surge of \u003cstrong\u003e45.5%\u003c\/strong\u003e on one report date. The company plans to form a dedicated research team and incorporate a new wholly owned Israeli subsidiary to operate the Initiative.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eFinancial Metric\u003c\/th\u003e\n\u003cth\u003eAmount\/Ratio\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$6.2 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCurrent Ratio\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e5.36\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (Past 3 Years)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.31 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-554.52%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-481.16%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Margin\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e38.74%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAnalyst projections include sales growth of \u003cstrong\u003e17%\u003c\/strong\u003e for the current year and a projected EPS of \u003cstrong\u003e$60.86\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Sustained, if they can establish an early lead in applying this novel computational method to their therapeutic targets.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe initiative focuses on developing quantum-enabled tools to:\u003c\/li\u003e\n\u003cli\u003eAccurately predict how proteins fold into their 3D shapes.\u003c\/li\u003e\n\u003cli\u003eModel how proteins interact with potential drugs (protein-ligand interactions).\u003c\/li\u003e\n\u003cli\u003eAccelerate the discovery of new drugs by providing highly precise predictions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 8. High Gross Profit Potential from New IP\n\u003c\/h2\u003e\n\u003cp\u003eThe transition to commercializing the MUSE™ intellectual property represents a potential shift in SciSparc’s financial profile, moving from high R\u0026amp;D expenditure toward device sales margins.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eWhile TTM Revenue ending September 2025 was only \u003cstrong\u003e$1.31 million\u003c\/strong\u003e with a Gross Profit of \u003cstrong\u003e$0.51 million\u003c\/strong\u003e, the MUSE™ IP acquisition is for a device market where margins are typically higher than early-stage drug development, offering a clearer path to positive gross margins. The GERD device market was valued at approximately \u003cstrong\u003e$2.5 billion\u003c\/strong\u003e in 2024 and is projected to reach \u003cstrong\u003e$3.03 billion\u003c\/strong\u003e by 2030.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe potential for high margins on a near-term product line contrasts sharply with the negative operating income of \u003cstrong\u003e-$7.44 million\u003c\/strong\u003e TTM ending September 2025. The company's TTM R\u0026amp;D Expenses were \u003cstrong\u003e$1.9 million\u003c\/strong\u003e against TTM Revenue of \u003cstrong\u003e$1.31 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe specific market positioning and cost structure of the MUSE™ system are protected by the acquired IP, which includes patents and trademarks. The technology leverages Xylo's prior commercialization success, which included securing a \u003cstrong\u003e$3 million\u003c\/strong\u003e upfront payment in China in 2019.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eThe organization must now pivot resources from pure R\u0026amp;D burn to commercialization planning for this device asset. The current organizational structure is reflected in its TTM Selling, General \u0026amp; Admin expenses of \u003cstrong\u003e$6.04 million\u003c\/strong\u003e. The acquisition itself is structured to avoid immediate cash outflow, involving the issuance of ordinary shares representing \u003cstrong\u003e19.99%\u003c\/strong\u003e of the issued and outstanding share capital upon closing.\u003c\/p\u003e\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\n\u003cp\u003eTemporary, as market entry will invite competition, but the initial IP position grants a head start. The GERD device market includes established competitors such as Olympus Corporation and Medtronic Plc.\u003c\/p\u003e\n\u003cp\u003eKey Financial and Market Metrics:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTTM Revenue (ending Sep '25): \u003cstrong\u003e$1.31 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTTM Gross Profit (ending Sep '25): \u003cstrong\u003e$0.51 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eTTM Operating Income (ending Sep '25): \u003cstrong\u003e-$7.44 million\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eProjected GERD Market CAGR (2025-2030): \u003cstrong\u003e3.24%\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eAcquisition Consideration: Issuance of shares equal to \u003cstrong\u003e19.99%\u003c\/strong\u003e of outstanding capital\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eComparative Financial and Market Data:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (TTM Sep '25)\u003c\/td\u003e\n\u003ctd\u003eMarket Context \/ Prior Deal\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.31 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Gross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.51 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTTM Operating Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-$7.44 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGERD Device Market Value (2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$2.5 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGERD Device Market Projection (2030)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3.03 billion\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXylo China Upfront Payment (2019)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$3 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition Consideration Equity Stake\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e19.99%\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSciSparc Ltd. (SPRC) - VRIO Analysis: 9. Operational Efficiency in Managing R\u0026amp;D Burn\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Despite a net loss, understanding the cost structure is key; the organization needs to ensure spending is on future growth. For the TTM ending Sep '25, Operating Expenses were \u003cstrong\u003e\\$7.94 million\u003c\/strong\u003e, with R\u0026amp;D at \u003cstrong\u003e\\$1.9 million\u003c\/strong\u003e and SG\u0026amp;A at \u003cstrong\u003e\\$6.04 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The ability to maintain a relatively controlled R\u0026amp;D spend compared to SG\u0026amp;A (which is high relative to revenue) is a point of scrutiny, but the overall structure shows where the cash is going.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Cost structures are imitable, but the specific historical spending patterns are unique to SciSparc's operational history.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e The organization is organized to spend heavily on operations to support the pipeline, but the high SG\u0026amp;A relative to revenue (TTM Sep '25) suggests overhead management is an area for improvement.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e None, as high operating expenses relative to low revenue (\u003cstrong\u003e\\$1.31 million\u003c\/strong\u003e TTM) indicate a reliance on external funding, which is a vulnerability.\u003c\/p\u003e\n\u003cp\u003eThe following table summarizes key financial metrics for the Trailing Twelve Months (TTM) ending September '25, in millions of USD, illustrating the operational cost structure:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eTTM (Sep '25)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.31\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of Revenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.8\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross Profit\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$0.51\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch \u0026amp; Development Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$1.9\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, General \u0026amp; Admin. Expenses\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$6.04\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Expenses (Total)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e\\$7.94\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating Income\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e-\\$7.44\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eFinance:\u003c\/strong\u003e The expected share issuance for the Xylo IP deal involves issuing ordinary shares representing \u003cstrong\u003e19.99%\u003c\/strong\u003e of SciSparc's outstanding share capital upon closing, or alternatively, issuing pre-funded warrants to purchase ordinary shares. This transaction is intended to support the commercialization strategy for the MUSE system in North America, Europe, and Latin America, building on Xylo's prior licensing agreement which secured an upfront payment of \u003cstrong\u003e\\$3 million\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eKey external market data relevant to the acquired IP:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eGlobal GERD device market valuation in 2024: \u003cstrong\u003e\\$2.5 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected global GERD device market valuation by 2030: \u003cstrong\u003e\\$3.03 billion\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eProjected Compound Annual Growth Rate (CAGR) for the market (2025 to 2030): \u003cstrong\u003e3.24%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eA definitive 13-week cash flow projection incorporating the expected share issuance by Friday cannot be provided without specific weekly cash flow estimates or the closing date of the definitive agreements. The projection would incorporate the non-cash consideration (share issuance) and potential cash proceeds if pre-funded warrants are issued, alongside existing cash burn rates derived from the TTM operating losses.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516255756437,"sku":"sprc-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/sprc-vrio-analysis.png?v=1740213443","url":"https:\/\/dcf-model.com\/es\/products\/sprc-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}